- Home
- NNVC
NNVC
NanoViricides Inc.
as 11-14-2024 12:35pm EST
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
| Founded: | 2005 | Country: | United States |
| Employees: | N/A | City: | SHELTON |
| Market Cap: | 17.7M | IPO Year: | N/A |
| Target Price: | $6.50 | AVG Volume (30 days): | 130.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.00 - $3.59 | Next Earning Date: | 11-22-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest NanoViricides Inc. News
NNVC Breaking Stock News: Dive into NNVC Ticker-Specific Updates for Smart Investing
Associated Press Finance
11 hours ago
NanoViricides: Fiscal Q1 Earnings Snapshot
ACCESSWIRE
11 days ago
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
ACCESSWIRE
24 days ago
NanoViricides President Dr. Diwan to Present at the PODD Conference
ACCESSWIRE
a month ago
NanoViricides President Dr. Diwan Interviwed in PODD Podcast; He Explains the Revolutionary Clinical Stage Broad-Spectrum Antiviral NV-387, and the Potential of the Platform to Revolutionize Fields Beyond Virology
Insider Monkey
a month ago
NanoViricides Inc. (NNVC): Best Nanotech Penny Stock to Buy
ACCESSWIRE
a month ago
NanoViricides to Present at the Global AMR Summit 2024 Tomorrow
ACCESSWIRE
2 months ago
NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include RSV, Influenza, MPOX/Smallpox, COVID
ACCESSWIRE
2 months ago
NanoViricides Executes an Agreement Encompassing All Antiviral Drug Treatments With Theracour, Including “Trojan Horse” Drugs
Compare NNVC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NNVC NanoViricides Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.